US · HQL
Tekla Life Sciences Investors
- Sector
- Financial Services · Asset Management
- Headquarters
- Philadelphia, MA 02110
- Website
- teklacap.com
Price · as of 2023-09-30
$17.55
Market cap 480.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $959.67 | +5,368.21% |
| Intrinsic Value(DCF) | $3.72 | -78.8% |
| Graham-Dodd Method(GD) | $18.16 | +3.45% |
| Graham Formula(GF) | $24.26 | +38.21% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2009 | $2.01 | $5,270.09 | $7,500.78 | $1,195.90 | $60,342.05 |
| 2010 | $2.41 | $46,434.90 | $0.00 | $11,371.34 | $135,716.55 |
| 2011 | $3.00 | $174,419.91 | $5,261.29 | $13,028.12 | $0.00 |
| 2012 | $4.16 | $81,489.79 | $0.00 | $32,007.33 | $1,465,168.33 |
| 2013 | $6.01 | $78,899.54 | $12,060.47 | $48,377.61 | $0.00 |
| 2014 | $8.41 | $432,346.08 | $12,283.71 | $46,841.03 | $350,889.36 |
| 2015 | $8.21 | $57,924.10 | $11,083.34 | $33,797.45 | $116,691.66 |
| 2016 | $6.92 | $256.95 | $0.00 | $29.84 | $0.00 |
| 2017 | $8.39 | $242.04 | $0.00 | $37.89 | $3,126.01 |
| 2018 | $8.21 | $72.88 | $8.53 | $27.62 | $0.00 |
| 2019 | $9.04 | $37.14 | $5.43 | $1.35 | $0.00 |
| 2020 | $10.86 | $319.58 | $0.00 | $46.08 | $7,450.37 |
| 2021 | $11.56 | $27.80 | $0.00 | $34.88 | $60.30 |
| 2022 | $9.99 | $37.36 | $0.00 | $0.00 | $80.65 |
| 2023 | $9.29 | $959.67 | $1.06 | $18.16 | $24.26 |
AI valuation
Our deep-learning model estimates Tekla Life Sciences Investors's (HQL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $959.67
- Current price
- $17.55
- AI upside
- +5,368.21%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.72
-78.8% upside
Graham-Dodd
$18.16
+3.45% upside
Graham Formula
$24.26
+38.21% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HQL | Tekla Life Sciences Inves… | $17.55 | 480.73M | +5,368% | -79% | +3% | +38% | 11.76 | 0.65 | 6.68 | 4.96 | — | 0.65 | 46.41% | -13.31% | 56.75% | 5.59% | -1.32% | 5.47% | 0.00 | — | — | — | 0.00 | -11941.00% | 2361.00% | — | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | -47.23 | — | 6.29 | 236.59 |
| CCAP | Crescent Capital BDC, Inc… | $12.66 | 468.33M | +25,800% | +22,018% | +150,480% | +27% | 0.01 | 0.00 | 3.14 | -292.25 | — | 0.00 | 78.02% | 76.15% | 22.09% | 18.94% | 0.03% | 8.24% | 0.00 | 2.07 | — | — | -297.00 | -5327.00% | 965.00% | -970.00% | 15.25% | — | 0.02% | 0.34% | 0.00% | 6425.72% | -253.36 | -403.27 | -192.93 | 0.03 |
| CION | CION Investment Corporati… | $7.98 | 412.33M | +131% | -47% | — | — | 16.83 | 0.70 | 4.00 | 48.88 | — | 0.70 | 32.17% | 23.81% | 23.74% | 3.99% | 1.75% | 1.72% | 1.34 | 0.35 | 4.30 | 4.30 | 32.09 | -6379.00% | -2568.00% | 5925.00% | 15.45% | 6.80 | 4.56% | 15.68% | 263.90% | 17.67% | 48.88 | 18.85 | 11.64 | 0.32 |
| ECC | Eagle Point Credit Compan… | $4.03 | 527.26M | +484% | +70% | — | — | 7.98 | 0.68 | 5.52 | 10.18 | — | 0.68 | 84.18% | 73.73% | 69.26% | 9.60% | 8.49% | 6.53% | 0.29 | 4.66 | 2.22 | 2.21 | 2.69 | -5057.00% | -1494.00% | 2153.00% | 16.17% | 2.36 | 10.28% | 25.58% | 204.00% | 25.58% | 10.18 | 8.40 | 7.51 | 0.69 |
| GAIN | Gladstone Investment Corp… | $13.69 | 545.16M | +98% | -58% | — | — | 7.17 | 0.94 | 5.21 | 13.92 | — | 0.94 | 68.57% | 72.67% | 72.67% | 13.17% | 7.14% | 6.72% | 0.91 | 2.31 | 3.69 | 3.69 | 6.76 | -2794.00% | -1288.00% | 3249.00% | 24.34% | 18.46 | 12.46% | 13.02% | 93.30% | 13.02% | 13.92 | 7.98 | 10.12 | 0.87 |
| GIG | GigCapital7 Corp. | $10.60 | 358.11M | — | — | — | — | 993.04 | 1785.59 | — | 992.48 | — | 1785.59 | 0.00% | — | — | — | — | — | 0.00 | — | 8.95 | 7.75 | -0.57 | — | — | — | 0.00% | -4.74 | — | 0.00% | 0.00% | 0.00% | -3754.05 | — | — | 6.97 |
| GLAD | Gladstone Capital Corpora… | $18.20 | 411.19M | +289% | -47% | — | +295% | 7.97 | 0.96 | 3.20 | 6.78 | — | 0.96 | 87.27% | 55.53% | 40.14% | 12.10% | 9.75% | 6.76% | 0.83 | 4.02 | 9.90 | 9.90 | 2.99 | -4124.00% | 2037.00% | 124648.00% | 9.41% | 10.08 | 5.29% | 11.97% | 95.50% | 11.97% | 10.31 | 19.00 | 5.73 | 1.16 |
| MCI | Barings Corporate Investo… | $20.00 | 409.45M | +72% | -52% | -89% | +13% | 10.73 | 1.11 | 8.82 | 11.30 | — | 1.11 | 87.60% | 86.73% | 82.20% | 10.41% | 9.94% | 8.89% | 0.13 | 21.07 | 1.99 | 1.99 | 0.79 | -385.00% | 510.00% | -1213.00% | 7.37% | 2.05 | 7.61% | 8.35% | 89.60% | 8.35% | 10.94 | 14.59 | 9.48 | 4.26 |
| PNNT | PennantPark Investment Co… | $4.98 | 325.17M | +574% | -27% | — | — | — | 0.79 | 4.40 | 29.83 | — | 0.79 | 50.27% | 42.48% | 39.39% | 0.00% | 2.77% | 0.00% | 1.59 | 0.85 | 0.39 | 0.42 | 19.47 | -3333.00% | -1988.00% | -13835.00% | 18.09% | 0.45 | 5.59% | 18.58% | — | 28.17% | 29.83 | 15.92 | 12.67 | 0.03 |
| SOR | Source Capital, Inc. | $48.23 | 396.75M | +3% | -37% | +40% | +276% | 8.37 | 0.92 | 8.15 | 8.37 | — | 0.92 | 100.00% | 97.36% | 97.36% | 10.92% | 10.92% | 10.55% | 0.00 | — | 0.20 | 0.14 | 0.00 | -2646.00% | 3126.00% | — | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 8.37 | — | 8.15 | 9.31 |
| TCPC | BlackRock TCP Capital Cor… | $4.09 | 347M | +3,518% | -10% | +136% | +26,503% | 1.26 | 0.58 | 1.73 | — | 3.82 | 0.58 | 0.00% | 0.00% | 54.42% | 40.22% | 0.00% | 15.57% | 0.00 | 0.00 | — | — | — | 3291.00% | 87176.00% | -4715.00% | 44.35% | — | 13.19% | 6.27% | 7.90% | 318.56% | — | 1.86 | 1.43 | 0.38 |
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
- CEO
- Daniel R. Omstead
- Employees
- 0
- Beta
- 0.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.72 ÷ $17.55) − 1 = -78.8% (DCF, example).